Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Defining the Complexity of EGFR Endocytosis in Cancer

Oncotarget

April 27, 2023
In a new editorial perspective, researchers delve into the complex mechanisms underlying EGFR endocytosis and its potential as a therapeutic target. continue reading »

Differential Silencing of STAT3 Isoforms Leads to Changes in STAT3 Activation

News

April 26, 2023
PRESS RELEASE: On April 24, 2023, a new research paper was published in Oncotarget, entitled, “Differential silencing of STAT3 isoforms leads to changes in STAT3 activation.” continue reading »

Tumor Necroptosis Promotes Metastasis by Modulating Tumor-Host Immunity

News

April 24, 2023
PRESS RELEASE: On April 10, 2023, a new editorial paper was published in Oncotarget, entitled, “Tumor necroptosis promotes metastasis through modulating the interplay between tumor and host immunity.” continue reading »

CA 19-9 and CEA in Prognosis of Duodenal Adenocarcinoma: A Retrospective Study

News

April 18, 2023
PRESS RELEASE: On April 15, 2023, a new research paper was published in Oncotarget, entitled, “Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study.” continue reading »

Cancer Prevention With Rapamycin

News

April 17, 2023
PRESS RELEASE: On April 14, 2023, a new research perspective was published in Oncotarget, entitled, “Cancer prevention with rapamycin.” continue reading »